Literature DB >> 14653388

Antibody responses of periodontitis patients to gingipains of Porphyromonas gingivalis.

Satoru Inagaki1, Kazuyuki Ishihara, Yuriko Yasaki, Satoru Yamada, Katsuji Okuda.   

Abstract

BACKGROUND: Arginine- and lysine-specific cysteine proteinases (arg-gingipain: Rgp, lys-gingipain: Kgp) are major virulence factors of Porphyromonas gingivalis. Recent reports have suggested that antibodies against gingipains can play a protective role against infection by P. gingivalis. The purpose of this study was to evaluate the IgG responses of patients with periodontitis to functional domains of gingipains.
METHODS: A group of 29 periodontitis patients and 10 periodontally healthy subjects (control group) were recruited into this study. We prepared three recombinant fragments of rgp A (catalytic domain; r-Rgp CAT) and two hemagglutinin domains (r-Rgp 44, and r-Rgps 15-27) corresponding to amino acid residues 228 to 719, 720 to 1136, and 1137 to 1704, respectively. One fragment of the Kgp catalytic domain (r-Kgp CAT) corresponding to amino acid residues 229 to 737 and expressed in Escherichia coli was also used. IgG antibody levels to these recombinant proteins in sera from the subjects were determined by an enzyme-linked immunosorbent assay (ELISA).
RESULTS: We found that IgG levels against r-Rgp 44 and r-Rgps 15-27 in sera obtained from the patients were significantly higher than those in the healthy group (P<0.01). In contrast, no significant differences in IgG levels against r-Rgp CAT and r-Kgp CAT were found between the control and patient groups. The IgG responses to P. gingivalis sonic extracts, r-Rgp 44 and r-Rgps 15-27, were related to probing depth in sera from patients, but those to r-Rgp CAT and r-Kgp CAT were not.
CONCLUSION: The present findings suggest that the low responsiveness of IgG antibody against the catalytic domains of gingipain, r-Rgp CAT, and r-Kgp CAT is a key factor in infection by P. gingivalis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14653388     DOI: 10.1902/jop.2003.74.10.1432

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  6 in total

1.  Cleavage of IgG1 and IgG3 by gingipain K from Porphyromonas gingivalis may compromise host defense in progressive periodontitis.

Authors:  Bjarne Vincents; Arndt Guentsch; Dominika Kostolowska; Ulrich von Pawel-Rammingen; Sigrun Eick; Jan Potempa; Magnus Abrahamson
Journal:  FASEB J       Date:  2011-07-18       Impact factor: 5.191

2.  HGP44 induces protection against Porphyromonas gingivalis-Induced alveolar bone loss in mice.

Authors:  Kyotaro Muramatsu; Eitoyo Kokubu; Takahiko Shibahara; Katsuji Okuda; Kazuyuki Ishihara
Journal:  Clin Vaccine Immunol       Date:  2011-03-23

3.  Vaccines against periodontitis: a forward-looking review.

Authors:  Jeom-Il Choi; Gregory J Seymour
Journal:  J Periodontal Implant Sci       Date:  2010-08-30       Impact factor: 2.614

4.  Recognition of Porphyromonas gingivalis gingipain epitopes by natural IgM binding to malondialdehyde modified low-density lipoprotein.

Authors:  S Pauliina Turunen; Outi Kummu; Kirsi Harila; Marja Veneskoski; Rabah Soliymani; Marc Baumann; Pirkko J Pussinen; Sohvi Hörkkö
Journal:  PLoS One       Date:  2012-04-05       Impact factor: 3.240

5.  In silico analysis as a strategy to identify candidate epitopes with human IgG reactivity to study Porphyromonas gingivalis virulence factors.

Authors:  Ellen Karla Nobre Dos Santos-Lima; Kizzes Araújo Paiva Andrade Cardoso; Patrícia Mares de Miranda; Ana Carla Montino Pimentel; Paulo Cirino de Carvalho-Filho; Yuri Andrade de Oliveira; Lília Ferreira de Moura-Costa; Teresa Olczak; Isaac Suzart Gomes-Filho; Roberto José Meyer; Márcia Tosta Xavier; Soraya Castro Trindade
Journal:  AMB Express       Date:  2019-03-11       Impact factor: 3.298

Review 6.  Strategies for the inhibition of gingipains for the potential treatment of periodontitis and associated systemic diseases.

Authors:  Ingar Olsen; Jan Potempa
Journal:  J Oral Microbiol       Date:  2014-08-18       Impact factor: 5.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.